Consensus Statement Says Testosterone Therapy Is Warranted in Women with Hypoactive Sexual Desire Disorder

Although testosterone administration has no definitive indications in women — and FDA-approved testosterone-containing products for women are lacking — clinicians have prescribed various preparations to alleviate a variety of symptoms in women despite uncertain benefits and risks. A task force representing several international societies has developed a position statement based on findings from randomized controlled trials lasting ≥12 weeks.

Key points include:

• Testosterone therapy is indicated only for postmenopausal women with hypoactive sexual desire disorder (HSDD), with evidence suggesting moderate therapeutic effects.

• Doses yielding premenopausal physiologic blood levels of testosterone should be used.

• Although available data have not doc…